ZURICH, May 25 (Reuters) - Roche Holding AG's potential blockbuster drug Mircera has been cleared by European authorities, who recommended allowing sales to treat anaemia linked to kidney disease.
-- Dose Adjustments Considered to be one of the Main Causes of Haemoglobin Instability in Chronic Kidney Disease Patients A new analysis has shown that once-monthly Mircera(R) maintains stable ...
ZURICH, Dec 15 (Reuters) - Swiss drugmaker Roche Holding AG said on Friday the U.S. Food and Drug Administration had extended the review period for its anaemia drug Mircera for patients with chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results